Core Viewpoint - Scorpius Holdings, Inc has announced a partnership with Celltheon Corporation to enhance cell line development services for clients, utilizing Celltheon's proprietary GOLDILOCKS™ platform, which aims to streamline the transition from research to biomanufacturing [1][2]. Company Overview - Scorpius Holdings, Inc is an integrated contract development and manufacturing organization (CDMO) focused on advancing biologic programs, offering a range of analytical testing, process development, and manufacturing services at its facilities in San Antonio, TX [5]. - Celltheon Corporation specializes in innovative technologies for biotherapeutics, providing end-to-end solutions for drug developability, cell line development, and process development [4]. Partnership Details - The collaboration allows clients to integrate with Scorpius' program management and quality systems while transferring a research cell bank (RCB) to Scorpius' facilities for further biomanufacturing [2]. - Celltheon will provide additional services such as antibody discovery, variant screening, and comparability studies to Scorpius clients [2]. - The first client under this partnership is focused on scaling up to GMP manufacturing with Scorpius [2]. Leadership Commentary - The CEO of Scorpius expressed enthusiasm about the partnership, emphasizing the shared mission to deliver high-quality, flexible services to early-stage biotechs and academic researchers [3]. - The VP of Business Development at Celltheon highlighted the commitment to help clients overcome early development challenges and expedite the delivery of biotherapeutics to patients [3].
Scorpius Holdings Announces Collaboration with Celltheon Corporation, a U.S.-Based Cell Line Development Company; First Client Signed Under New Partnership Agreement